-
Trump Promises Lower Interest Rates, but the President Doesn’t Control Those
The Federal Reserve sets interest rates, and it operates independently of the White House. But rates could come down as inflation cools.
-
How to Incorporate Mindfulness into Your Daily Routine
In today’s fast-paced world, our minds are constantly bombarded with information, distractions, and stress. It’s no wonder that many of us struggle to find inner peace and balance in our daily lives. But what if I told you that there is a simple yet powerful tool that can help you achieve just that? It’s called…
-
How to Create a BudgetFriendly Travel Itinerary
Traveling is an exciting and enriching experience, but it can also be expensive. From flights to accommodations to activities, the costs of traveling can add up quickly. However, with careful planning and budgeting, it is possible to create a budget-friendly travel itinerary that allows you to explore new places without breaking the bank. In this…
-
RegFi Episode 42: Beyond the Breach: The CISO’s Role as a Strategic Risk Manager
RegFi co-hosts Jerry Buckley and Sherry Safchuk welcome Orrick partner Aravind Swaminathan for a conversation exploring the critical and evolving role of the Chief Information Security Officer in today’s corporate landscape.. Aravind emphasizes the importance of organizational culture in the success of cybersecurity efforts and the need for CISOs to be not just technical experts…
-
Janssen Pharms., Inc. v. Teva Pharms. USA, Inc. – Invega Sustenna® (Paliperidone Palmitate)
Case Name: Janssen Pharms., Inc. v. Teva Pharms. USA, Inc., No. 2022-1258, 2022-1307, 2024 WL 1355733 (Fed. Cir. Apr. 1, 2024) (Circuit Judges Dyk, Prost, and Hughes presiding; Opinion by Prost, J.) (Appeal from D.N.J., Cecchi, J.)….By: Robins Kaplan LLP
-
How the Timing of Director Review May Affect Co-Pending Litigation
Director Review at the Patent Trial and Appeal Board (PTAB) remains a hot topic in patent law. The Director first established an interim process for Director Review in the wake of the Supreme Court’s 2021 decision in United States v. Arthrex, and the USPTO issued a Notice of Proposed Rulemaking, discussed here, that would make…
-
FDA and FTC Issue Joint Warning Letters for Copycat Delta-8 THC Food Products
The U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) issued warning letters on July 16, 2024, to five companies for illegally selling and introducing into the market copycat food products containing delta-8 tetrahydrocannabinol (THC)……By: Perkins Coie
-
AI and Invention: USPTO Issues More Guidance
On July 17, 2024, the U.S. Patent Office issued additional guidance regarding patentability and inventorship concerns relating to Artificial Intelligence. This guidance expands upon prior guidelines, as discussed in a previous alert….By: Woods Rogers
-
FDA’s Second Untitled Letter of the Year – An Apparently Tough Choice Between Raising Awareness and Public Safety for Anaphylaxis Drugs
On July 17, 2024—but just recently posted to the Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) website—FDA issued its second untitled letter (letter) of the year to Kaleo, Inc. (Kaleo) over social media promotion of AUVI-Q® (epinephrine injection, USP). The social content was posted on the personal Instagram…
-
Third Circuit Affirms Lone Pine Order and Ensuing Dismissals in In re Zostavax MDL
In March 2022, the In re Zostavax MDL court entered a Lone Pine order requiring plaintiffs who claimed to have developed shingles as a result of using the Zostavax vaccine to produce certain test results supporting causation. In December 2022, the court dismissed 1,189 cases for failure to comply with that Lone Pine order……By: Faegre…
